SALLuting a new biomarker in hepatocellular carcinoma

Journal Title: Annals of Hepatology - Year 2014, Vol 13, Issue 2

Abstract

Authors and Affiliations

Andrea L. Inghilesi, Fabio Marra

Keywords

Related Articles

Antimitochondrial antibody serocoversion post-liver transplant during hepatitis C treatment with peginterferon α, ribavirin and telaprevir

Pegylated interferon alpha (PEG-IFN α), a key component of chronic hepatitis C therapy, has been linked to the development of auto-antibodies and autoimmune disease. We report the first case of antimitochondrial antibody...

Preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: a single center analysis

Background and aim. The effect of preoperative transcatheter arterial chemoembolization (TACE) on the short- and long-term outcome of resectable hepatocellular carcinoma (HCC) is controversial. We conducted a retrospecti...

Drug-induced fatty liver disease: An overview of pathogenesis and management

Over the past decades, many drugs have been identified, that can potentially induce steatohepatitis in the predisposed individual. Classically this has been incriminated to amiodarone, perhexiline, and 4,4’-diethylaminoe...

Download PDF file
  • EP ID EP78390
  • DOI -
  • Views 114
  • Downloads 0

How To Cite

Andrea L. Inghilesi, Fabio Marra (2014). SALLuting a new biomarker in hepatocellular carcinoma. Annals of Hepatology, 13(2), 305-307. https://europub.co.uk/articles/-A-78390